Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia

Summary

To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.

Timeline

Start

2014-03

Primary completion

2015-03

Completion

2015-03

Drugs

Indications